Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF[1][2].
Molekulargewicht:
578.42
Reinheit:
99.70
CAS Nummer:
[1715025-32-3]
Formel:
C26H27BrF3N5O2
Target-Kategorie:
ERK,Raf
Anwendungsbeschreibung:
MCE Product type: Dye Reagents
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten